share_log

Truist Adjusts Price Target on CRISPR Therapeutics to $100 From $120, Maintains Buy Rating

Truist Adjusts Price Target on CRISPR Therapeutics to $100 From $120, Maintains Buy Rating

Truist將crispr therapeutics的目標價從$120調整至$100,維持買入評級。
MT Newswires ·  08/12 06:10  · 評級/大行評級

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論